Clinical Trial Update: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the ongoing Phase 1/Phase 2 study MK-6070-003 evaluating Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in adults w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Gocatamig (MK-6070)
• Infinatamab Deruxtecan (MK-2400)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 1, Phase 2 | Status: RECRUITING